Cellyan Biotechnology Co., Ltd

Cellyan Biotechnology Co., Ltd, an investment holding company, engages in the over the counter (OTC) pharmaceutical business in Hong Kong and Mainland China. The company provides OTC pharmaceutical cross-border procurement and distribution and e-commerce supply chain services. It also offers custom clearance, drugs enlisting, warehouse, and other logistics services. The company serves e-commerce platform logistics partners, merchants, and pharmaceutical distributors. The company was formerly known as Hong Kong Pharma Digital Technology Holdings Limited and changed its name to Cellyan Biotechnology Co., Ltd in December 2025. Cellyan Biotechnology Co., Ltd was incorporated in 2023 and is based in Yau Tong, Hong Kong.

Cellyan Biotechnology Co., Ltd trades as HKPD on NASDAQ. The company is classified in Healthcare / Medical - Pharmaceuticals and reports in USD.

The current profile places the business in Medical - Pharmaceuticals. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Detailed operating-segment data is not available for this symbol yet.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

Cellyan Biotechnology Co., Ltd can be compared against peers such as Art's-Way Manufacturing Co., Inc., Addentax Group Corp., Freightos Limited Ordinary shares, Jayud Global Logistics Limited, Lakeside Holding Limited, New Century Logistics (BVI) Limited.

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of $5.43M, beta of 2.34, and return on equity of N/A.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

HKPD currently shows total debt of N/A and beta of 2.34. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

No recent SEC-style filings are available for this symbol yet.

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: http://www.9zt.hk

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.